Risperdal | The American Association For Justice

Risperdal

Litigation Packet: Document Details

Packet Name: Risperdal

Updated Date: 3/31/2015 | Created Date: 3/24/2014 | Number of Pages: 1371
Summary of Packet:
  • Risperdal, an atypical (second generation) antipsychotic originally approved for the treatment of schizophrenia and Bipolar I disorder in adults but marketed off-label to children and adolescents, can increased prolactin levels and cause irreversible gynecomastia
  • Includes case screening criteria, a sample complaint, and an overview of litigation
  • Includes pleadings and orders from three mass tort actions in Pennsylvania, New Jersey, and California
  • AAJ Education speaker papers, resources from the U.S. Food and Drug Administration, and a survey of medical journal articles
Access to the AAJ Exchange and Litigation Packets is restricted to plaintiff attorneys who are AAJ Regular, Sustaining, Life, Presidents Club, or Leaders Forum members.